Buscar
ALX Oncology Holdings Inc
ALXOAñadir a la lista de seguimiento
1.940USD
-0.010-0.51%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
103.94MCap. mercado
PérdidaP/E TTM
Más Datos de ALX Oncology Holdings Inc Compañía
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Información de ALX Oncology Holdings Inc
Símbolo de cotizaciónALXO
Nombre de la empresaALX Oncology Holdings Inc
Fecha de salida a bolsaJul 17, 2020
Director ejecutivoLettmann (Jason)
Número de empleados80
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 17
Dirección323 Allerton Avenue
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504667125
Sitio Webhttps://alxoncology.com/
Símbolo de cotizaciónALXO
Fecha de salida a bolsaJul 17, 2020
Director ejecutivoLettmann (Jason)
Ejecutivos de ALX Oncology Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
263.61K
+19.23%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
78.00K
+3.85%
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
33.68K
-2.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Dr. Alan Sandler, M.D.
Dr. Alan Sandler, M.D.
Director
Director
--
--
Mr. Chris H. Takimoto, M.D., Ph.D.
Mr. Chris H. Takimoto, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
263.61K
+19.23%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
78.00K
+3.85%
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
33.68K
-2.68%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ALX Oncology Holdings Inc?
Los cinco principales accionistas de ALX Oncology Holdings Inc son: Mr. Jason Lettmann
¿Cuántas instituciones poseen acciones de ALX Oncology Holdings Inc (ALXO)?
A fecha de 2026Q1, 244 instituciones poseen acciones de ALX Oncology Holdings Inc, con un valor de mercado combinado de aproximadamente 51.67M, lo que representa el 38.46% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3929077.00.